Companies ›Healthcare ›ALRTF

ALRTF — OTC Medical Equipment & Supplies

ALR Technologies SG Ltd.

$0,02

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

—

Net margin

—

Debt / equity

—

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

$0,02

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

ALR Technologies SG Ltd. operates in the Medical Devices industry within the Healthcare Equipment & Supplies sector, though specific operational details and revenue sources are not disclosed in the available data.

Business. ALR Technologies SG Ltd. (ALRTF) is a healthcare company engaged in the medical devices industry, specifically within the medical equipment and supplies sector. The firm operates as a product-sale business without publicly disclosed operating segments or geographic breakdowns. Headquartered in Singapore, the company is primarily listed on the OTC market under the ticker ALRTF.

Classification70 %

SectorHealthcare

Business sectorHealthcare Equipment & Supplies

Industry groupMedical Equipment, Supplies & Distribution

IndustryMedical Equipment & Supplies

ActivityMedical Devices

Generated · model-assisted

Sell-side consensus

—consensus pending

— buy— hold— sell

Avg 12m price target—

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts

—

not yet wired

Ownership

—

not yet wired

Profitability

—

not yet wired

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning ALRTF.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to ALRTF. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

ALR Technologies SG Ltd. (ALRTF) is a healthcare company engaged in the medical devices industry, specifically within the medical equipment and supplies sector. The firm operates as a product-sale business without publicly disclosed operating segments or geographic breakdowns. Headquartered in Singapore, the company is primarily listed on the OTC market under the ticker ALRTF.

Classification70 %

SectorHealthcare

Business sectorHealthcare Equipment & Supplies

Industry groupMedical Equipment, Supplies & Distribution

IndustryMedical Equipment & Supplies

ActivityMedical Devices

AI synthesis

GENERATED

(a) Capital structure and liquidity cannot be assessed as the financial snapshot is unavailable, leaving balance sheet items, cash flow, and debt levels undefined. The valuation snapshot indicates a market price of $0.018, but without share count or market capitalization data, leverage and liquidity ratios remain unknown.

(b) Profitability and returns are unquantifiable due to the absence of income statement data. There are no cohort medians or industry context metrics provided to benchmark performance against peers in the Medical Equipment & Supplies sector.

Key takeaways

Financial data is entirely unavailable, preventing any fundamental analysis of profitability, liquidity, or valuation multiples.
The stock experienced a high-severity price drop of -26.471% on 2026-07-20, driven by volume 2.245x above average.
Risk assessment is inconclusive due to missing financial snapshots and source documents.
Classification confidence is moderate (0.70) for the Medical Devices industry.
No segment, geographic, or historical growth data is present to support operational insights.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation

Market price

$0,02

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

—

Net cashⓘ

—

Current ratioⓘ

—

Debt / equityⓘ

—

ROAⓘ

—

ROEⓘ

—

Cash conversionⓘ

—

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

—

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

Peer comparison8 peers · vs ALRTF · multiples and returns

TMO—

Thermo Fisher Scientific Inc

$574,03

214,1B USD

P/E

29,4x

— vs self

Div yield

0,3 %

— vs self

ROE

12,9 %

— vs self

DHR—

Danaher Corp

$197,50

140,1B USD

P/E

38,2x

— vs self

Div yield

—

— vs self

ROE

6,9 %

— vs self

GEHC—

GE HEALTHCARE TECHNOLOGIES INC.

$69,72

31,9B USD

P/E

13,6x

— vs self

Div yield

0,2 %

— vs self

ROE

19,5 %

— vs self

PHG—

PHG

—

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

BSX—

Boston Scientific Corp

$48,54

72,6B USD

P/E

—

— vs self

Div yield

—

— vs self

ROE

—

— vs self

ISRG—

INTUITIVE SURGICAL, INC.

$376,00

133,2B USD

P/E

287,7x

— vs self

Div yield

—

— vs self

ROE

3,6 %

— vs self

A—

Agilent Technologies Inc

$139,80

39,6B USD

P/E

29,0x

— vs self

Div yield

0,8 %

— vs self

ROE

19,3 %

— vs self

EW—

Edwards Lifesciences Corp

$88,82

51,6B USD

P/E

44,3x

— vs self

Div yield

—

— vs self

ROE

10,4 %

— vs self

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

— missing data

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskUnknown

Liquidity riskUnknown

Benchmarks vs cohort

No cohort benchmark data available for this issuer yet.

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Regulatory filings
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data
Reference data

How metrics are computed

Market Price
input from market-data provider (delayed close or quote-shim mid)

Source documents

ALR Technologies SG Ltd. company facts · 2026-07-26
ha_price_move fired on ALRTF · 2026-07-26

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

ALRTFCanonical

OTC · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskUnknown

Liquidity riskUnknown

Evidence & claims

From filings & derived data

R&D expense (YoY) (2025-12-31 vs 2024-12-31): -10.2%Derived (calculated)
Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -10.0%Derived (calculated)
Debt-to-equity (FY 2025-12-31): -1.00xDerived (calculated)
Return on equity (FY 2025-12-31): 55.3%Derived (calculated)
EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -33.3%Derived (calculated)
Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 9.9%Derived (calculated)
Total assets (YoY) (2025-12-31 vs 2024-12-31): -40.4%Derived (calculated)
Return on assets (FY 2025-12-31): -46,561.0%Derived (calculated)
Net income (YoY) (2025-12-31 vs 2024-12-31): -38.9%Derived (calculated)
Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -21.3%Derived (calculated)
Pre-tax income (annual): USD -2.26MSEC XBRL filing
Total operating expenses (annual): USD 2.88MSEC XBRL filing
Operating cash flow (annual): USD -1.87MSEC XBRL filing
Total assets (annual): USD 47.37KSEC XBRL filing
Net income (annual): USD -22.06MSEC XBRL filing
EPS (diluted) (annual): USD-PER-SHARES -0SEC XBRL filing
Interest expense (annual): USD -19.74MSEC XBRL filing
R&D expense (annual): USD 793.33KSEC XBRL filing
Total liabilities (annual): USD 39.91MSEC XBRL filing
Shareholders' equity (annual): USD -39.86MSEC XBRL filing
Return on assets (FY 2024-12-31): -19,978.8%Derived (calculated)
EPS (diluted) (YoY) (2024-12-31 vs 2023-12-31): -200.0%Derived (calculated)
Net income (YoY) (2024-12-31 vs 2023-12-31): -112.4%Derived (calculated)
Operating cash flow (YoY) (2024-12-31 vs 2023-12-31): 5.1%Derived (calculated)

Showing 24 of 60 surfaced claims.

Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data · Reference data Premium coverage

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread